SCHEMBL12426409

SCHEMBL12426409

CCOC(=O)C1=CN(C)C=C(SC(=O)N(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.43
KDM4E B2RXH2 5/20 0.35
ALDH1A1 P00352 4/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GAA P10253 2/20 0.34
POLB P06746 2/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALOX12 P18054 2/20 0.33
ADORA2B P29275 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 3/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426405 0.75 ACHE (0.55) ACHEKDM4EALDH1A1L3MBTL1GAA
SCHEMBL12426466 0.74 ACHE (0.38) ACHEKDM4EALDH1A1L3MBTL1GAA
SCHEMBL12426406 0.73 ACHE (0.45) ACHEKDM4EALDH1A1L3MBTL1GAA
SCHEMBL12426382 0.72 ACHE (0.66) ACHEKDM4EALDH1A1GAAPOLB
SCHEMBL12426450 0.67 ACHE (0.60) ACHEKDM4EALDH1A1L3MBTL1GAA
SCHEMBL14067651 0.65 TSHR (0.42) ACHEKDM4EALDH1A1L3MBTL1GAA
SCHEMBL12426463 0.65 ACHE (0.42) ACHEKDM4EALDH1A1GAAPOLB
SCHEMBL12426379 0.63 ACHE (0.61) ACHEKDM4EALDH1A1GAAHPGD
SCHEMBL19895799 0.62 TSHR (0.59) KDM4EALDH1A1L3MBTL1GAAHSD17B10
SCHEMBL9797391 0.62 KDM4E (0.48) KDM4EALDH1A1L3MBTL1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 EP disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP ACHE 17/4885KDM4E 1927/4885ALDH1A1 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.